Edesa Biotech, Inc. — Form SCHEDULE 13D/A
Filed August 25, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Pardeep Nijhawan filed an amended Schedule 13D/A regarding beneficial ownership in Edesa Biotech, Inc. (market cap ~$14M). The filing document references are provided but specific details on share count, percentage ownership, transaction amounts, or what changed from the prior disclosure are not legible or included in the available text excerpts.
Why this rating
Schedule 13D amendments are routine disclosure filings when beneficial ownership thresholds or details require updating. Without concrete data on shares, percentages, or material changes relative to the company's size, this appears administrative.
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.